PTC Therapeutics to Acquire Agilis Biotherapeutics Acquisitions, Angelman Syndrome, Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, Biologics License Application (BLA), Biotech, Business, CNS, Gene Therapy, Monogenic Diseases, Neurodegenerative Diseases, Neurological Disorders, Product Pipelines PTC Therapeutics Inc. announced an agreement to acquire Agilis Biotherapeutics Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system. Read more July 19, 2018/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2018-07-19 16:10:222018-07-21 00:16:03PTC Therapeutics to Acquire Agilis Biotherapeutics
